Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
May 28, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
May 20, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 ...
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:05 ET
|
Lisata Therapeutics, Inc.
Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call...
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
May 08, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
May 02, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
April 23, 2024 07:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and JINAN, China, April 23, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing...
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
April 09, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
April 03, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
March 21, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
February 29, 2024 16:05 ET
|
Lisata Therapeutics, Inc.
Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at...